PCM
GEVA

Prelude Capital Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Prelude Capital Management’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-6,638
Closed -$551K – 2405
2014
Q1 		$551K Buy
6,638
+4,058
+157% +$375K 0.07% 361
2013
Q4 		$167K Buy
2,580
+20
+0.8% +$1.19K 0.03% 668
2013
Q3 		$162K Buy
+2,560
New +$126K 0.03% 597

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Prelude Capital Management's GEVA Position: Q2 2014 in Review

Prelude Capital Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2014, closing a stake of 6,638 shares — an estimated $551K sold.

Prelude Capital Management first reported a position in GEVA in Q3 2013 and held it in 3 quarters. The position peaked at $551K in Q1 2014. 115 funds tracked by Wall St. Rank hold GEVA as of Q2 2014.

  • Prelude Capital Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2014 after selling out during the quarter.
  • Prelude Capital Management sold 6,638 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2014, an estimated $551K.
  • Prelude Capital Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013 and held it in 3 quarters.
  • Prelude Capital Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $551K in Q1 2014.
  • 115 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2014.

Based on Prelude Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.